# Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

> **NCT05549180** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 84 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo
- **DRUG:** Dovato 50Mg-300Mg Tablet + Biktarvy placebo

## Key facts

- **NCT ID:** NCT05549180
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2024-02-13
- **Final completion:** 2024-08-07
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549180, "Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05549180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*